SLC5A2 and neoplasm: A total of 31,755 monotherapy reports, including 17,653 GLP-1 RA and 14,102 SGLT-2 inhibitor reports, were used for the analysis of 191 unique thyroid hyperplasia or neoplasm reports in the GLP-1 RA group and 7 reports in the SGLT-2 group, respectively (Tables1 ,  2).